| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
CLINICAL SCIENCE |
Division of Nephrology, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
Correspondence to Dr. Judith A. Miller, Division of Nephrology, 11EN-221, Toronto General Hospital, University Health Network, 200 Elizabeth Street, Toronto, Ontario, Canada, M5G 2C4. Phone: 416-340-4966; Fax: 416-340-4951; E-mail: judith.miller{at}utoronto.ca
ABSTRACT. We have previously shown that users of oral contraceptive (OC) medications exhibit increased plasma levels of angiotensin II (Ang II) with only modest hemodynamic consequences, suggesting estrogen-mediated Ang II type 1 (AT1) receptor downregulation. Accordingly, in 10 women who were OC users and 10 women who, as OC nonusers, served as controls, all mean age 26 ± 1 yr, we examined the renal and peripheral hemodynamic response to graded Ang II infusion, plasma and urine cyclic guanosine monophosphate (cGMP) levels as a surrogate marker for AT1 and/or AT2 receptor-mediated activation of the nitric oxide pathway, and AT1 receptor expression in skin biopsies. The OC nonusers were studied during the follicular and luteal phases of the menstrual cycle, whereas OC users were studied once during the 21-d medication phase. Subjects ingested a controlled sodium diet for 7 d before each study. Renal hemodynamic function was assessed using standard inulin and p-aminohippurate clearance techniques. AT1 receptor mRNA levels in skin biopsy samples were assessed using a real-time PCR protocol. In response to graded Ang II infusion, OC users exhibited renal and peripheral hemodynamic responses that were augmented compared with those of OC nonusers, in conjunction with evidence of increased tissue AT1 receptor expression. Plasma cGMP levels and 24-h urinary cGMP excretion did not differ. These data suggest that, contrary to our original hypothesis, OC use does not appear to be associated with AT1 receptor downregulation. The factor protecting OC users from the hemodynamic impact of increased Ang II levels remains elusive.
This article has been cited by other articles:
![]() |
D. Z. I. Cherney, J. W. Scholey, R. Nasrallah, M. G. Dekker, C. Slorach, T. J. Bradley, R. L. Hebert, E. B. Sochett, and J. A. Miller Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1336 - F1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Z. I. Cherney, J. W. Scholey, D. C. Cattran, A. K. Kang, J. Zimpelmann, C. Kennedy, V. Lai, K. D. Burns, and J. A. Miller The effect of oral contraceptives on the nitric oxide system and renal function Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1539 - F1544. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Miller, D. Z. Cherney, J. A. Duncan, V. Lai, K. D. Burns, C. R.J. Kennedy, J. Zimpelmann, W. Gao, D. C. Cattran, and J. W. Scholey Gender Differences in the Renal Response to Renin-Angiotensin System Blockade J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2554 - 2560. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Ahmed, P. Hovind, H.-H. Parving, P. Rossing, D. A. Price, L. M. Laffel, M. C. Lansang, R. Stevanovic, N. D.L. Fisher, and N. K. Hollenberg Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy Diabetes Care, August 1, 2005; 28(8): 1988 - 1994. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673